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Background and aims: Heparin/protamine micro/nanoparticles (LH/P-MPs) were recently developed as
low-molecular weight, biodegradable carriers for adipose-derived stromal cells (ADSCs). These particles
can be used for a locally delivered stem cell therapy that promotes angiogenesis. LH/P-MPs bind to the
cell surface of ADSCs and promote cell-to-cell interaction and aggregation of ADSCs. Cultured ADSC/LH/P-
MP aggregates remain viable. Here, we examined the ability of these aggregates to rescue limb loss in a
mouse model of hindlimb ischemia.
Methods: Unilateral hindlimb ischemia was induced in adult male BALB/c mice by ligation of the iliac
artery and hindlimb vein. For allotransplantation of ADSCs from the same inbred strain, we injected ADSC
alone or ADSC/LH/P-MP aggregates or control medium (sham-treated) directly into the ischemic muscles.
Ischemic limb blood perfusion, vessel density, and vessel area were recorded. The extent of ischemic limb
necrosis or limb loss was assessed on postoperative days 2, 7, and 14.
Results: Compared with the sham-treatment control, treatment with ADSCs alone showed modest ef-
fects on blood perfusion recovery and increased the number of a-SMA-positive vessels. Response to
ADSC/LH/P-MP aggregates was signiﬁcantly greater than ADSCs alone for every endpoint. ADSC/LH/P-MP
aggregates more effectively prevented the loss of ischemic hindlimbs than ADSCs alone or the sham-
treatment.
Conclusion: The LH/P-MPs augmented the effects of ADSCs on angiogenesis and reversal of limb
ischemia. Use of ADSC/LH/P-MP aggregates offers a novel and convenient treatment method and
potentially represents a promising new therapeutic approach to inducing angiogenesis in ischemic
diseases.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adipose-derived stromal cells (ADSCs) are a type of mesen-
chymal stem cell (MSC) with numerous advantages in regenerative
medicine, including multidirectional differentiation potential,
strong proliferative capacity, low immunogenicity, and no legal orDokkyo Medical University,
oto).
Ireland Ltd. This is an open accessethical issues associated with their use [1e4]. ADSCs can be
induced in vitro to differentiate into various cell lineages, including
adipocytes, osteocytes, chondrocytes, and endothelial cells [5].
Additionally, cultured ADSCs secrete signiﬁcant amounts of
angiogenic heparin-binding growth factors, such as basic ﬁbroblast
growth factor (b-FGF), hepatocyte growth factor (HGF), platelet-
derived growth factors (PDGFs), and vascular endothelial growth
factor (VEGF) as well as cytokines [6e8]. These stimulatory factors
may contribute to the reported ability of ADSCs to regenerate
damaged tissues, as demonstrated by transplanted human ADSC
culture signiﬁcantly stimulating angiogenesis [9]. Transplanted,article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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regenerating granulation and epithelial tissues of db/db diabetic
mice with some seeded ADSCs incorporated into blood vessels as
endothelial progenitor cells as indicated by double labeling of
microvessels with ﬂuorescence (DiI) and CD31 [7] Thus, ADSC
administration for tissue engineering represents a promising
angiogenesis therapy. In fact, ADSC transplantation induces neo-
vascularization in a mouse hindlimb ischemia model [10].
The clinical safety and efﬁcacy of ADSC implantation have been
reported in critical limb ischemia patients who were refractory to
other treatment modalities [11]. However, the therapeutic efﬁcacy
of cell-based therapy is often limited by poor performance during
engraftment, probably because of the rapid disappearance of
grafted cells from the injection site [12,13]. Grafted cells are “alien”
in terms of extracellular matrix constitution and hardly survive
ectopic micro-environments. Thus, ADSC transplant together with
an alternative cell-carrier may enhance ADSC survival.
We recently reported the development of low-molecular-
weight heparin/protamine micro/nanoparticles (LH/P-MPs) as cell
carriers for ADSC delivery into nude mice [14]. The LH/P-MPs bind
to the ADSC through cell surface heparin-binding proteins such as
integrins. Interactions between ADSCs and LH/P-MPs from ADSC/
LH/P-MP aggregates (approximately several hundred mm). These
aggregates strongly promote cellular viability in vitro and their
injection into nude mice accelerates subcutaneous neo-
vascularization [14].
In this study, using inbred mouse hindlimb ischemia model, we
investigated the feasibility of the ADSC/LH/P-MP aggregates to
ameliorate the impaired blood ﬂow and the limb loss. One day after
transplantation, ADSC increased systemic growth factors and cy-
tokines but the levels dropped down 7 days later. Although LH/P-
MP did not affect the initial surge of systemic growth factors, it
augmented the angiogenic actions of ADSC per se. Thus, the com-
bination of ADSC and LH/P-MP are a feasible strategy to ameliorate
hindlimb ischemia.
2. Materials and methods
2.1. Preparation of LH/P-MPs
LH/P-MPs were synthesized as described previously [15,16].
Brieﬂy, 0.3 mL of protamine sulfate solution (10 mg/mL; Mochida
Pharmaceutical Co., Tokyo, Japan) was added dropwise to 0.7 mL of
a Dalteparin sodium LH solution (6.4 mg/mL; Kissei Pharmaceutical
Co., Tokyo, Japan), vortexed for 2 min, and washed twice with
phosphate-buffered saline (PBS) and centrifuged at 4900 g for
5 min (MX-50; Tomy Seiko Co., Ltd, Tokyo, Japan) to remove non-
reactants. The precipitates were resuspended in 1 mL of Dulbec-
co's Modiﬁed Eagle's Medium (DMEM; Life Technologies Oriental,
Tokyo, Japan). Upon drying, >6 mg of dry LH/P-MPs were obtained
from each mL of resuspended LH/P-MPs solution. The ﬁnal solution
contained 60 mg of LH/P-MPs resuspended in 1 mL of DMEM.
2.2. Preparation of ADSCs and ADSC/LH/P-MP aggregates
All animal experiments adhered to the Guidelines for Animal
Experimentation of Dokkyo Medical University, with all efforts made
to minimize the animal numbers and suffering. ADSCs from inbred
mice were prepared as previously described [7,14] with several
modiﬁcations. Brieﬂy, BALB/c mice (Japan SLC Co., Ltd, Shizuoka,
Japan) adipose tissue from the inguinal region was removed,
minced, transferred to C tubes (Miltenyi Biotec Corp., Tokyo, Japan),
and digested with 0.1% collagenase type I (Wako Pure Chemical
Industries, Ltd., Osaka, Japan) and 0.2% Dispase type II (Life Tech-
nologies) for 1 h at 37 C. Digested tissue was mechanically andgently dispersed with a MACS Dissociator (Miltenyi Biotec Corp.)
using the installed software program “m_brain01-02” every 10min.
The suspension was passes through a 100-mm ﬁlter (BD Falcon, NJ,
USA), centrifuged at 420 g for 5 min (LC-200; Tomy Seiko Co., Ltd,
Tokyo, Japan) and resuspended in DMEM. The cell concentration
was determined using a hemocytometer. ADSCs (4  106 cells per
mouse) were mixed with 160 mL of LH/P-MPs (60 mg/mL) and
incubated for 1 h at 37 C to prepare ADSC/LH/P-MP aggregates.
2.3. Evaluation of cell viability in culture
ADSCs were maintained in DMEM containing 10% heat-
inactivated fetal bovine serum (FBS), 100 U/mL penicillin G, and
100 mg/mL streptomycin. To prepare ADSC/LH/P-MP aggregates, LH/
P-MPs (1.4 mg of dried particles/mL) were added to a 15-mL
polypropylene conical tube (BD Falcon, NJ, USA) with occasional
shaking at 37 C for the indicated time periods. After incubation,
ADSCs alone or ADSC/LH/P-MP aggregates were removed from the
medium, resuspended in 100 mL freshmediumwith or without FBS,
and transferred to a new 96-well tissue culture plate. To count
living ADSCs, 10 mL WST-1 reagent (Cell Counting Kit, Dojindo,
Kumamoto, Japan) was added, incubated for 1 h at 37 C, and the
optical density (OD) was read at 450 nm on an Immuno Mini plate
reader (Nunc InterMed Japan, Tokyo, Japan) after an additional at
0.5, 10, 24, 48, and 96 h.
2.4. Analysis of ADSC-secreted growth factors and cytokines
ADSCs from inbred male BALB/c mice were plated on 10-cm
plastic (control) or LH/P-MP-coated tissue culture plates, and
ADSC/LH/P-MP aggregateswere plated on 10-cm plastic suspension
culture plates (each 1  106 cells per dish). LH/P-MP-coated tissue
culture plates were coated for 3 h at 4 C with 3 mL of LH/P-MP
solution. The coating solution was then removed, and the plates
were gently washed with PBS. ADSC-conditioned medium was
collected 3 days after plating. At the end of culturing, supernatants
were collected and stored at 80 C until analysis. The presence of
interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating
factor (GM-CSF), b-FGF, PDGF-bb, and VEGF was analyzed using the
BioPlex system (Bio-Rad Laboratories Co. Ltd., Tokyo, Japan). HGF
levels weremeasured in cell culture supernatants using an ELISA kit
(Institute of Immunology Co. Ltd., Tokyo, Japan) [7,14].
2.5. Mouse hindlimb ischemia model and experimental protocol
Inbred male BALB/c mice aged 9e11 weeks (n ¼ 18) were
anesthetized with an intraperitoneal injection of 90 mg/kg keta-
mine hydrochloride (Ketalar; Daiichi Sankyo Propharma Co., Ltd.,
Tokyo, Japan) and 10 mg/kg xylazine hydrochloride (Celactal; Bayer
Yakuhin, Ltd., Osaka, Japan). All mice underwent ligation of the
right external iliac artery and hindlimb vein to produce right hin-
dlimb ischemia [17]. Mice were randomly allocated into three
groups (n ¼ 6 each): sham-treated (DMEM) group, ADSC group
(4  106 cells per mouse), and ADSC/LH/P-MP (ADSC/LH/P-MP ag-
gregates) group. Treatments were injected at eight different sites
(5  105 cells; 20 mL per site) on the adductor muscles of the
ischemic limb immediately after surgery.
2.6. Hindlimb blood ﬂow assessment
Hindlimb blood ﬂow was analyzed using a laser Doppler blood
perfusion imager (PeriScan PIM III; Perimed AB, Stockholm, Swe-
den) on postoperative day 0 (within 24 h of the operation) and days
2, 7, and 14. Depilatory creamwas used to remove excess limb hair
before imaging. Mice were placed on a heating plate at 38 C to
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was calculated from scanned images as perfusion units (PU) and
serial changes in the ischemic (right) hindlimb were compared
between groups. Changes in blood perfusion for the contralateral
non-ischemic (left) hindlimb blood perfusion were also assessed to
control for variation resulting from interference by ambient light
and temperature.
2.7. Evaluation of hindlimb survival
Hindlimb survival was evaluated by morphologic observation
on postoperative days 2, 7, and 14 and compared between groups.
Limb ischemia was classiﬁed normal (limbs with a normal
appearance), slight necrosis (toes or digits exhibited darkening),
severe necrosis (entire foot exhibited darkening), and limb loss
(auto-amputation) [18]. Hindlimb survival time was deﬁned as the
time post-surgery until the appearance of severe necrosis.
2.8. Analysis of growth factors and cytokines in the peripheral blood
Mouse peripheral blood was collected on postoperative days 1
and 7 and analyzed for IL-6, GM-CSF, b-FGF, PDGF-bb, VEGF and
HGF concentrations using a multiplex Luminex kit (R&D Systems,
Inc., Minneapolis, MN, USA). Magnetic beads were quantiﬁed using
Luminex-200 (Luminex, Austin, TX, USA), and data were analyzed
using xPONENT software version 3.1. Reference standards and
samples were run in duplicate accordance with the manufacturers'
instructions. Growth factor and cytokine concentrations were
determined from standard curves prepared on each plate and were
expressed as pg/mL or ng/mL.
2.9. Immunohistochemistry
Ischemic thigh adductor skeletal muscle tissue samples were
obtained on postoperative days 7 and 14 and processed for
immunohistochemistry and blinded assessment of blood vessel
density and area. The presence of collateral vessels that bypassed
the occluded segment of the femoral artery was assessed by
immunohistochemical staining with rabbit anti a-smooth muscle
actin (a-SMA) (Abcam Cambridge, MA) and evaluation of ﬁve
random microscopic ﬁelds per slide by light microscopy (BX-53;
Olympus Corp., Tokyo, Japan). a-SMA-positive vessel luminal area
was quantiﬁed as the percentage of the total tissue area in a high
power ﬁeld (400) using Adobe Photoshop CS6 (Adobe Systems
Inc., San Jose, CA). A threshold was selected and used to identify
positive pixels on each slide. The percent areawas calculated as the
percentage of positive pixels relative to the total number of pixels in
each view. Adjacent tissue sections were stained with hematoxylin
and eosin [19].
2.10. Statistical analysis
Data are expressed as the mean ± standard deviation (SD).
Statistical signiﬁcance was evaluated using unpaired Student's t
tests for two-group comparisons. One-way analysis of variance
(ANOVA) followed by Scheffe's post-hoc test was used to compare
3 groups. Serial changes were evaluated using repeated-measures
ANOVA. Probability values <0.05 were considered signiﬁcant.
3. Results
3.1. Effect of LH/P-MPs on ADSCs
When ADSCs were suspended in DMEM in the presence of LH/P-
MPs, LH/P-MPs induced ADSC/LH/P-MP aggregate formationwithin3 h, with and without FBS (Fig. 1A). ADSC viability, as indicated by
the OD value gradually decreased both with (1.64 ± 0.08 at 0.5 h to
0.37 ± 0.05 at 96 h, p < 0.01) and without (1.63 ± 0.07 at 0.5 h to
0.17 ± 0.03 at 96 h, p < 0.01) FBS. When ADSC/LH/P-MP aggregates
were subsequently cultured, ADSCs maintained their viability for at
least 96 h with FBS (1.56 ± 0.05 at 0.5 h to 1.66 ± 0.10 at 96 h),
although the viability did decrease without FBS (1.65 ± 0.06 at 0.5 h
to 1.22 ± 0.08 at 96 h, p < 0.01) (Fig. 1B).
3.2. ADSC production of growth factors and cytokines
Cultured ADSCs secreted substantial amounts of growth factors
and cytokines over a 3-day period. Coating of the plastic tissue
culture plate with LH/P-MPs signiﬁcantly lowered the secreted
growth factors and cytokines (Table 1), indicating that the material
absorbs secreted proteins onto the plastic plate. On the other hand,
the spheroid culture of ADSC/LH/P-MP further lowered the secreted
growth factors and cytokines (Table 1). Thus, the formation of
ADSC/LH/P-MP aggregates, rather than sheet-like structure, is and
efﬁcient way to absorb secreted proteins.
3.3. Blood ﬂow recovery following injection of ADSC/LH/P-MP
aggregates
Representative laser Doppler blood perfusion imaging (Fig. 2A)
of hindlimb perfusion on postoperative days 0, 2, 7, and 14 was
compared between treatment groups. On postoperative day 2,
ischemic hindlimb blood perfusionwas signiﬁcantly lower than the
contralateral control hindlimb in all groups. Although the sham-
treated and ADSC groups showed lower blood perfusion until
postoperative day 14, perfusion was remarkably restored in the
ADSC/LH/P-MP group. Although ischemic limb blood perfusionwas
higher with ADSC than sham treatment on postoperative day 14
(84.95 ± 15.32 PU vs. 23.9 ± 16.51 PU, p < 0.05), it was far higher in
the ADSC/LH/P-MP group (135.75 ± 25.66 PU, p < 0.05 for both
comparisons). ADSC/LH/P-MP group ischemic limb blood perfusion
was one-half that of the contralateral control hindlimb on post-
operative day 7 (89.12 ± 26.37 vs. 173.61 ± 25.80, p < 0.05), but was
nearly even with the control level (171.88 ± 20.86) on day 14
(Fig. 2B).
3.4. Prevention of limb loss by ADSC/LH/P-MP aggregate injection
Representative images of an ischemic limb in each group on
postoperative days 0, 2, 7, and 14 are shown in Fig. 2C. In the sham-
treated group, 4/6 mice (67%) developed limb loss, whereas the
remaining 2 (33%) showed severe ischemia on postoperative day
14. In the ADSC group, 1/6 mice (17%) had limb loss and 3/6 mice
(50%) had severe ischemia on postoperative day 14. Conversely, the
ADSC/LH/P-MP group did not experience limb loss or severe
ischemia. Moreover, the limbs of 4/6 mice (67%) appeared normal
on postoperative day 14 (Fig. 2D). The median hindlimb survival
time in the sham, ADSC, and ADSC/LH/P-MP groups was approxi-
mately 9, 15, and 28 days, respectively.
3.5. Peripheral blood growth factors and cytokines
Concentrations of IL-6, GM-CSF, b-FGF, PDGF-bb, VEGF, and HGF
on postoperative days 1 and 7 are presented in Fig. 3. The factors
GM-CSF (43.88 ± 16.69 pg/mL [ADSC], 36.49 ± 5.74 pg/mL [ADSC/
LH/P-MP], vs. 0.27 ± 0.03 pg/mL [sham-treated]; p < 0.01), b-FGF
(231.74 ± 71.18 pg/mL [ADSC], 340.75 ± 80.94 pg/mL [ADSC/LH/P-
MP], vs. 95.03 ± 40.66 pg/mL [sham-treated]; p < 0.01), PDGF-bb
(486.06 ± 189.68 pg/mL [ADSC], 492.84 ± 115.38 pg/mL [ADSC/
LH/P-MP], vs. 160.21 ± 113.2 pg/mL [sham-treated]; p < 0.01),
Fig. 1. (A) Morphological appearance of ADSC/LH/P-MP aggregates in cell culture. ADSCs suspended in the presence of LH/P-MPs formed ADSC/LH/P-MP aggregates within 3 h, both
with and without FBS. (B) ADSC cell culture viability assay. Cell culture optimal density gradually decreased in ADSC suspensions, with and without FBS. When ADSC/LH/P-MP
aggregates were cultured, ADSCs remained viable for at least 96 h. FBS maintained ADSC/LH/P-MP aggregate viability. **p < 0.01. ADSC: adipose-derived stromal cell; LH/P-MP:
low-molecular-weight heparin/protamine micro/nanoparticle; OD: optical density; FBS: fetal bovine serum.
Table 1
Secretion of growth factors and cytokines from ADSCs and adsorption to ADSC/LH/P-MP aggregates and LH/P-MP-coated plates.
Culture IL-6 (pg/mL) GM-CSF (pg/mL) b-FGF (pg/mL) PDGF-bb (pg/mL) VEGF (ng/mL) HGF (pg/mL)
ADSC/LH/P-MP aggregates 260 ± 35 5.2 ± 1.1 16 ± 1.6 2.2 ± 0.3 5.2 ± 1.1 260 ± 11
LH/P-MP-coated plate 430 ± 65 8.0 ± 1.2 21 ± 2.0 2.4 ± 0.2 15.4 ± 2.2 520 ± 65
Normal plate 1010 ± 150 21 ± 2.0 110 ± 23 11.0 ± 1.4 75 ± 1.1 2200 ± 2800
After culturing ADSCs for 3 days, secreted cytokines present in the culture medium per onemillion cells were measured using the BioPlex system. These cells were viable for at
least 3 days in suspension culture conditions [14]. Data are presented as the mean ± SD.
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MP], vs. 36.91 ± 3.97 ng/mL [sham-treated]; p < 0.05), and HGF
(1191.47 ± 525.55 pg/mL [ADSC]; p < 0.05, 1069.79 ± 121.28 pg/mL
[ADSC/LH/P-MP]; p < 0.01, vs. 274.28 ± 10.74 pg/mL [sham-
treated])dwere signiﬁcantly higher in the ADSC and ADSC/LH/P-
MP groups than in the sham-treated group on day 1. Of note, on
day 1, IL-6 was higher in the sham-treated (185.54 ± 24.85 pg/mL)
than in the control (i.e. without ischemia) group (9.71 ± 5.91 pg/
mL). These factors were lower in all groups by day 7.3.6. Immunohistochemistry
Fig. 4A shows representative microscopic ﬁndings for a-SMA-
positive vessels located within ischemic hindlimb muscles on
postoperative days 7 and 14. Data are expressed as both pericytes
and smooth muscle cells located within mature blood vessels. The
ADSC group showed an increase in the number of a-SMA-positive
vessels on days 7 and 14 compared with the sham-treated group
(3.5 ± 0.71 vs. 1.1 ± 0.32 on day 7, p < 0.01; 3.8 ± 0.79 vs. 1.4 ± 0.52
on day 14, p < 0.01). In the ADSC/LH/P-MP group, a-SMA-positive
vessels were even more abundant (4.3 ± 0.48 on day 7, p < 0.01;
5.0 ± 0.94 on day 14, p < 0.01) (Fig. 4B). The ADSC and ADSC/LH/P-
MP groups showed an increase in a-SMA-positive vessel lumen
area compared with the sham-treated group on days 7 and 14
(5.2% ± 1.34% [ADSC], 7.86% ± 2.03% [ADSC/LH/P-MP], vs.
0.47% ± 0.16% [sham-treated] on day 7; 6.55% ± 1.26% [ADSC],
9.61% ± 2.90% [ADSC/LH/P-MP], vs. 0.64% ± 0.24% [sham-treated]
on day 14; p < 0.01). Staining was higher in the ADSC/LH/P-MP
than in the ADSC group (p < 0.01 on days 7 and 14) (Fig. 4C).
These increases in a-SMA-positive vessel number and lumen area
provide a histological basis for the increased blood ﬂow and tissue
viability in the ischemic limbs of ADSC and ADSC/LH/P-MP group
mice.4. Discussion
This study, demonstrated that LH/P-MPs promote cell-to-cell
interaction and mouse ADSC aggregation. When cultured in sus-
pension, ADSCs in aggregates but not ADSCs alonemaintained their
viability for at least 96 h in the presence of FBS. These results
suggested that the ADSC/LH/P-MP aggregates enhance trans-
planted ADSC survival in vivo. In a mouse hindlimb ischemiamodel,
ADSC/LH/P-MP aggregates weremore effective than ADSCs alone at
preventing hind limb loss, although ADSCs alone were more
effective than the sham treatment. Compared to ADSCs alone, the
ADSC/LH/P-MP aggregates stimulated greater angiogenesis as
demonstrated by an increase in a-SMA-positive vessels and greater
improvement in blood perfusion as demonstrated by laser Doppler
blood perfusion imaging. The enhanced angiogenesis and blood
perfusion achieved with ADSC/LH/P-MP aggregates likely resulted
in the decreased ischemic limb loss. These results suggest that LH/
P-MPs can augment the ability of ADSCs to ameliorate hindlimb
ischemia.
Heparinoids, such as LH or heparan sulfate, are well-known co-
factors that enhance the activities of heparin-binding growth fac-
tors [20]. LH/P-MPs are able to adsorb and enhance the activities of
various heparin-binding growth factors and cytokines that are
released from ADSCs, including IL-6, GM-CSF, b-FGF, PDGF-bb,
VEGF, and HGF (Table 1). Similarly, LH/P-MPs show high afﬁnities
for interactions with FGF-2, HGF, and various heparin-binding
growth factors derived from platelet-rich plasma (PRP) [8]. Also
they were efﬁciently adsorbed by LH/P-MPs, enhancing their ac-
tivities and protecting those growth factors from inactivation by
acidic or high heat environments and from protease degradation
in vitro. Furthermore, LH/P-MPs bind to the ADSC cell surface
through heparin-binding cell surface proteins such as integrins. The
interaction of ADSCs with LH/P-MPs results in ADSC/LH/P-MP
aggregate formation. Aggregate formation appear to promote
cellular viability in vitro [14]; thus, subcutaneous injection of mouse
Fig. 2. (A) Representative laser Doppler blood perfusion imaging. In all groups, postoperative day 2 ischemic limb blood perfusion was signiﬁcantly lower than the contralateral
control hindlimb. Although mice in the sham-treated and ADSC groups displayed lower blood perfusion until postoperative day 14, the ADSC/LH/P-MP group showed a remarkable
restoration of blood perfusion. (B) Quantitative assessment of serial changes in blood perfusion. On postoperative day 14, ischemic limb blood perfusion was higher with ADSC than
sham treatment but was highest with ADSC/LH/P-MP as compared with the other groups. ADSC/LH/P-MP ischemic limb blood perfusion was half that of the contralateral control
hindlimb on postoperative day 7 but was nearly similar by day 14. *p < 0.05. (C) Representative appearance of ischemic (right) and nonischemic (left) hindlimbs. (D) Necrotic limb
incidence in each group. ADSC: adipose-derived stromal cell; LH/P-MP: low-molecular-weight heparin/protamine micro/nanoparticle.
S. Kishimoto et al. / Atherosclerosis 249 (2016) 132e139136ADSC/LH/P-MP aggregates could stimulate cell proliferation and
migration, resulting in neovascularization in vivo [21]. ADSCs can
potentially release multiple angiogenic growth factors that can be
efﬁciently immobilized onto LH/P-MPs [8] or LH/P-MP-coated cul-
ture plates [22]. PRP/LH/P-MPs prevented limb loss in an adult
BALB/c-nu/nu male mouse-induced ischemic hindlimb model [23].
Thus, LH/P-MPs can enhance the angiogenic effects of ADSCs
through their ability to immobilize and to activate various angio-
genic factors.
The suggested angiogenic mechanism involves not only ADSCs
per se, but also endogenous inﬂammatory cells to induce the release
of multiple angiogenic factors [24,25]. Next, these angiogenic fac-
tors are adsorbed onto LH/P-MPs, permitting their stabilization and
bioavailability. The stability and availability of angiogenic factors
are therefore enhanced by LH/P-MPs. Finally, the activated angio-
genic factors markedly induce angiogenesis.
Surgical injury induced a systemic response on postoperative
day 1 in all groups other than in the control group. However, the
peripheral blood levels of ﬁve factors (GM-CSF, b-FGF, PDGF-bb,
VEGF, and HGF) were signiﬁcantly higher in the ADSC and ADSC/
LH/P-MP groups than in the sham-treated group and all had
decreased on day 7. Thus, we can explain the underlying mecha-
nisms in two steps. First, ADSC transplantation evokes a potent
local and systemic inﬂammatory response. Immune cells arerecruited from the bone marrow to locations throughout the body.
The burst of growth factor and cytokine production may exceed the
capacity of LH/P-MPs to adsorb them. At this stage, the effects of the
LH/P-MPs were not signiﬁcant (Fig. 3). Next, after the inﬂammation
subsides, the LH/P-MPs sustain the stability of local growth factors
and cytokines, enabling prolonged angiogenesis. ADSC is not the
sole player to produce the growth factors and the ADSC augments
immune cell mobilization. ADSC/LH/P-MPs, on the other hand, is
critical for the second step (coordinated repair) because of two
beneﬁcial effects (sustained survival of ADSC and stabilization of
released growth factors). Therefore, the combination of multiple
growth factors may be theoretically sufﬁcient to mimic the second
step. These mechanisms might explain how LH/P-MPs augmented
the ADSC potential to ameliorate hindlimb ischemia.
Heparin is used clinically as an antithrombotic agent, but at
doses that are limited by strong intrinsic anticoagulation to avoid
the potential for severe bleeding complications. However, LH shows
much lower anticoagulation activity than native heparin. Prot-
amine is also in clinical use to reverse heparin anticoagulant ac-
tivity following cardiopulmonary bypass or with heparin-induced
bleeding [15]. No bleeding complications were observed among
mice injected with LH/P-MPs in this study.
Peripheral arterial disease (PAD) is a major healthcare problem
in an aging society [26]. PAD commonly affects the arteries
Fig. 3. Expression of growth factors and cytokines in the peripheral blood. On postoperative day 1, GM-CSF, b-FGF, PDGF-bb, VEGF, and HGF concentrations were signiﬁcantly higher
in the ADSC and ADSC/LH/P-MP groups than in the sham-treated group, whereas IL-6 was higher in the sham-treated, ADSC, and ADSC/LH/P-MP groups than in the control group.
All groups showed decreased concentrations of all factors on day 7. Data are presented as the mean ± SD of 4 measurements. *p < 0.05; **p < 0.01 vs. sham-treated group;
##p < 0.01. ADSC: adipose-derived stromal cell; b-FGF: basic ﬁbroblast growth factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; HGF: hepatocyte growth factor;
IL-6: interleukin-6; LH/P-MP: low-molecular-weight heparin/protamine micro/nanoparticle; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor.
Fig. 4. Immunohistochemical staining using a-SMA to show tissue vascularization. (A) Representative microscopic images of a-SMA-positive vessels located in ischemic hindlimb
muscles. As compared with the sham-treated group, the ADSC group showed increased a-SMA-positive vessel density on postoperative days 7 and 14. More a-SMA-positive vessels
were visible in the ADSC/LH/P-MP group than in the other groups. (B) Mean number of a-SMA-positive vessels per 400 ﬁeld in sections of the adductor muscle (5 microscopic
ﬁelds per slide for each mouse). **p < 0.01 vs. sham-treated group; #p < 0.05; ##p < 0.01. (C) a-SMA-positive vessel lumen area was quantiﬁed as the percentage of the total tissue
area in a single high power ﬁeld (400). **p < 0.01 vs. sham-treated group; ##p < 0.01. ADSC: adipose-derived stromal cell; b-FGF: basic ﬁbroblast growth factor; a-SMA: alpha-
smooth muscle actin; LH/P-MP: low-molecular-weight heparin/protamine micro/nanoparticle.
S. Kishimoto et al. / Atherosclerosis 249 (2016) 132e139 137supplying the lower limbs. Because PAD is the most common cause
of atherosclerotic disease, it often complicates other atheroscleroticdiseases such as coronary artery disease and stroke. It is well
recognized that patients with PAD will probably die from a
S. Kishimoto et al. / Atherosclerosis 249 (2016) 132e139138cardiovascular disease [27]. Advanced PAD has been termed critical
limb ischemia. In critical limb ischemia patients, limb loss can occur
when the ischemia is not resolved by either percutaneous or sur-
gical revascularization procedures [28,29]. New approaches
involving stem cell therapy are being investigated. Bone marrow-
derived stromal cells (BMSCs) can improve limb ischemia after
injection and have prevented limb loss in experimental limb
ischemia models [30,31]. Studies have demonstrated the effec-
tiveness of autologous BMSCs in patients with ischemic limbs
[32e34]. MSCs are known to induce neovascularization in a hin-
dlimb ischemia model [35].
Adipose tissue is abundant in the human body and is constantly
reorganized through angiogenesis. Therefore, this tissue is an ideal
source of angiogenic MSCs. It has been shown that ADSCs have
characteristics similar to those of BMSCs [36,37]. The implantation
of in vitro cultured ADSCs in the mouse hindlimb ischemia model
showed proangiogenic activity [10]. Additionally, the safety and
effectiveness of autologous ADSCs implantation in critical limb
ischemia patients was reported [11]. Recently, an automated cell-
processing system for ADSC isolation has been developed, and its
safety and reproducibility have been assessed [38].
Intramuscular injection of ADSCs/LH/P-MPs may provide a new
therapeutic opportunity whereby ADSCs enhance angiogenesis and
vasculogenesis in ischemic tissues with impaired blood ﬂow.
ADSCs/LH/P-MPs preparation is simple, and ADSCs/LH/P-MPs can
be readily and directly administered into the ischemic region.
Because all components are in a clinical use and have already
passed a signiﬁcant number of toxicity and other tests, their safety
is well known. Drug repositioning (also referred to as drug repur-
posing), the process of ﬁnding new uses of existing drugs, has been
gaining popularity in recent years. Repurposed drugs such as these
can bypass much of the early cost and time needed to bring a drug
to the market [39].
5. Conclusion
Intramuscular injection of inbred mouse-derived ADSCs into
mouse ischemic hindlimbs promoted neovascularization and pre-
vented ischemic limb loss. LH/P-MPs present a potentially an
excellent biomaterial for immobilizing, retaining, and gradually
releasing various heparin-binding growth factors from ADSCs to
optimally sustain vascularization. Additionally, LH/P-MPs can act as
an efﬁcient cell carrier in vivo. In the future, ADSC pluripotency and
their secreted growth factors may be utilized in regenerative
medicine. The approach presented here using ADSCs/LH/P-MPs
may represent a valuable treatment option to enhance therapeu-
tic angiogenesis for tissue regeneration and to treat ischemic
disease.
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